CTOR (Citius Oncology) Current Ratio : 0.37 (As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Citius Oncology's current ratio for the quarter that ended in Sep. 2023 was 0.37.

Citius Oncology has a current ratio of 0.37. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Citius Oncology has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Citius Oncology's Current Ratio or its related term are showing as below:

CTOR' s Current Ratio Range Over the Past 10 Years
Min: 0.37 Med: 0.42 Max: 0.46
Current: 0.37

During the past 1 years, Citius Oncology's highest Current Ratio was 0.46. The lowest was 0.37. And the median was 0.42.

CTOR's Current Ratio is ranked worse than
92.86% of 1036 companies
in the Drug Manufacturers industry
Industry Median: 1.97 vs CTOR: 0.37

Citius Oncology Current Ratio Historical Data

The historical data trend for Citius Oncology's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Current Ratio Chart

Citius Oncology Annual Data

Trend

Sep22

Current Ratio

0.46

Citius Oncology Semi-Annual Data
	Sep22	Sep23
Current Ratio	0.46	0.37

Competitive Comparison of Citius Oncology's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Current Ratio distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Current Ratio falls into.

Citius Oncology Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Citius Oncology's Current Ratio for the fiscal year that ended in Sep. 2022 is calculated as

Current Ratio (A: Sep. 2022 )	=	Total Current Assets (A: Sep. 2022 )	/	Total Current Liabilities (A: Sep. 2022 )
	=	2.69	/	5.847
	=	0.46

Citius Oncology's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )	=	Total Current Assets (Q: Sep. 2023 )	/	Total Current Liabilities (Q: Sep. 2023 )
	=	7.735	/	21.047
	=	0.37

Citius Oncology (NAS:CTOR) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.

Citius Oncology Current Ratio Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Current Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.